This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

ORLANDO, Fla., (May 15, 2005) – Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that ...

THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...

THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa ...

BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...

The novel erythropoetic protein darbepoetin alfa exhibits enhanced biological activity and increased serum half-life compared with other erythropoetic agents used to treat chemotherapy-related anemia.

Am J Health Syst Pharm. 2005;62(24):2597-2603. Our investigation did not separate patients who were new to erythropoietic therapy from those who were continuing therapy. Drug product use between the ...

Conclusions: Non-inferiority with respect to tfn was demonstrated between DA 200 Q2W compared with EA 40,000 QW in a large, randomized phase 3 study. Similar efficacy was seen for Hb, PRO and safety ...

A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...

In a real-world study, UPCR decreased when darbepoetin alfa dose exceeded 60 μg in patients with diabetic kidney disease. Darbepoetin alfa treatment is associated with proteinuria lowering in a ...